- Renaissance Lakewood, LLC, a pharmaceutical contract development and manufacturing organisation (CDMO), has opened their new headquarters in Lakewood, NJ.
- The new facility spans 81,000 square feet, increasing the company’s GMP warehouse capacity and serving as the primary client engagement and administrative hub.
- The company’s expansion and facilities upgrade began in 2020, with the new campus master plan preparing for future growth.
Renaissance Lakewood, LLC, a pharmaceutical contract development and manufacturing organisation (CDMO), has announced the opening of their new headquarters at 1215 Paco Way in Lakewood, NJ. The new facility, which spans 81,000 square feet, will serve as the primary client engagement and administrative hub for the company, as well as significantly increase Renaissance Lakewood’s Good Manufacturing Practice (GMP) warehouse capacity.
The company’s president and CEO, Serge Maltais, emphasised the importance of creating an environment where clients feel welcome and supported. He said, “This brand-new space allows us to not only provide a technologically advanced engagement experience, but also offers our employees who work in this facility the opportunity to enjoy upgraded amenities and collaborative workspaces.”
Renaissance Lakewood, known for providing nasal and sterile injectable dosage forms, has developed and commercialized these products for U.S. and global markets. The company’s multi-million-dollar expansion and facilities upgrade of their now 370,000 square foot main campus footprint in Ocean County, NJ, began in 2020. This expansion consists of two new buildings as well as the renovation of their former headquarters building in Lakewood, NJ. An investment in state-of-the-art technology and equipment is also part of the modernized structures.
The 1200 Paco Way building has long served as the organization’s main manufacturing facility. Lab space, packaging operations, administrative offices, and warehousing capabilities are all housed at the 177,000 square foot location, which has remained open throughout the construction.
Maltais further added, “Expanding our footprint and making critical investments in our technology infrastructure are critically important to our success as a CDMO. We have spent nearly a decade upgrading our facilities and capabilities to meet the world-wide demand for our broad range of services. This new campus master plan is critical to preparing for the future growth of the company which includes nasal sprays, injectable products, R&D services, and secondary packaging.”
Overview of outsourcing trends 
